AnaBios
PrivateLast Round
M&A
Apr 4, 2023
Total Funding Raised
$12.5M
Company Overview
AnaBios is a biotechnology company that provides drug discovery services using its proprietary human-focused translational technologies to establish the safety and efficacy of novel compounds before clinical trials.
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AnaBios Comps
Public and private peers based on sector, stage, and business model.
AnaBios Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Apr 4, 2023 | ||||
| Private Equity | Jun 7, 2022 | ||||
| Grant | Sep 30, 2021 | ||||
| Series B | Dec 27, 2016 | ||||
| Series A | Apr 5, 2011 |
Key People
Founding team and executive leadership
AnaBios Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Neurological Disorders and Stroke | Grant |
| TCA Venture Group | Series A |
| ACE Fund | Series A |
| Principia SGR | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 19, 2026
Monthly visitors increased 118% MoM.
- Nov 8, 2025
Monthly visitors grew 50% MoM, reaching 5.1K.
AnaBios Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about AnaBios's valuation, stock price, and market status.
